Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Combined Therapy of Zanubrutinib and Zilovertamab in the Inhibition of Invasive Capability of Chronic Lymphocytic Leukemia Cells

Md Kamrul Hasan, George F. Widhopf II, Thomas J. Kipps

Blood (2023) 142 (Supplement 1): 6517.

https://doi.org/10.1182/blood-2023-191114

Published: 2023

Journal Articles

Cirmtuzumab (Zilovertamab) Eliminates ROR1 Positive Leukemia Stem Cells By Blocking Niche Dependent ROR1/WNT5a Signaling

Larissa Balaian, Mary Donohoe, Phoebe Mondala, George F. Widhopf II, Emanuela M. Ghia, Edward D. Ball, Anna Kulidjian, Inge Van Der Werf, Thomas J. Kipps, Catriona Jamieson

Blood (2022) 140 (Supplement 1): 3356–3357.

https://doi.org/10.1182/blood-2022-170128

Published: 2022

Journal Articles

Wnt5a Induces ROR1-Dependent NFkB Activation to Upregulate MMP9 and Enhance Invasiveness in Chronic Lymphocytic Leukemia

Md Kamrul Hasan, George F. Widhopf II, Thomas J. Kipps

Blood (2022) 140 (Supplement 1): 6991.

https://doi.org/10.1182/blood-2022-170209

Published: 2022

Journal Articles

Wnt5a Induces ROR1 to Interact Grb2 to Enhance Ras Activation in Chronic Lymphocytic Leukemia

Md Kamrul Hasan, Laura Z. Rassenti, George F. Widhopf II, Zhouxin Shen, Steven P. Briggs, Thomas J. Kipps

Blood (2021) 138 (Supplement 1): 247.

https://doi.org/10.1182/blood-2021-146332

Published: 2021

Journal Articles

Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax

Benjamin Heyman, MD, Michael Y. Choi, MD, Emanuela M. Ghia, PhD, George F. Widhopf II, PhD, Minya Pu, PhD, Emily Pittman, PhD, Karen Messer, PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD

Blood (2020) 136 (Supplement 1): 13.

https://doi.org/10.1182/blood-2020-134711

Published: 2020

Journal Articles

High-Level ROR1 and BCL2, Cancer-Stemness, and BCL2 Mutations Associate with Venetoclax Resistance in Chronic Lymphocytic Leukemia

Emanuela M. Ghia, PhD, Laura Z. Rassenti, PhD, Michael Y. Choi, MD, Elvin Chu, George F. Widhopf II, PhD, Thomas J. Kipps, MD PhD

Blood (2019) 134 (Supplement_1): 476.

https://doi.org/10.1182/blood-2019-131426

Published: 2019

Journal Articles

Wnt5a Induces ROR1-Dependent Upregulation of MMP9 and Enhanced Invasiveness in Chronic Lymphocytic Leukemia

Md Kamrul Hasan, PhD, Laura Z. Rassenti, PhD, George F. Widhopf II, PhD, Thomas J. Kipps, MD PhD

Blood (2019) 134 (Supplement_1): 4274.

https://doi.org/10.1182/blood-2019-131600

Published: 2019

Journal Articles

Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia

Yun Chen, Liguang Chen, Jian Yu, Emanuela M. Ghia, Michael Y. Choi, Ling Zhang, Suping Zhang, Elsa Sanchez-Lopez, George F. Widhopf, II, Karen Messer, Laura Z. Rassenti, Catriona Jamieson, Thomas J. Kipps

Blood (2019) 134 (13): 1084–1094.

https://doi.org/10.1182/blood.2019001366

Published: 2019

Includes: Multimedia, Supplemental data

Journal Articles

Cirmtuzumab Inhibits Non-Canonical Wnt Signaling without Enhancing Canonical Wnt/β-Catenin Signaling in Chronic Lymphocytic Leukemia

Han Zhang, PhD, Suping Zhang, PhD, Emanuela M. Ghia, PhD, Michael Y. Choi, MD, Jieyu Zhang, MS, Liguang Chen, PhD, George F. Widhopf II, PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD, PhD

Blood (2018) 132 (Supplement 1): 2652.

https://doi.org/10.1182/blood-2018-99-119606

Published: 2018

Journal Articles

Wnt5a Induces ROR1 Dependent Tyrosine Phosphorylation of DOCK2, and Enhanced Activation of ERK to Promote Proliferation of CLL Cells

Thomas Kipps, MD, Laura Z. Rassenti, PhD, George F. Widhopf II, PhD, Thomas J. Kipps, MD, PhD

Blood (2018) 132 (Supplement 1): 4404.

https://doi.org/10.1182/blood-2018-99-117175

Published: 2018

Journal Articles

Cirmtuzumab Blocks Production of Proinflammatory Factors By Inhibiting Wnt5a/ROR1 Induced Activation of NF-Kappa B in Chronic Lymphocytic Leukemia

Yun Chen, PhD, Michael Y. Choi, MD, Liguang Chen, PhD, Jian Yu, PhD, Ling Zhang, Emanuela M. Ghia, PhD, Elsa Sanchez-Lopez, PhD, George F. Widhopf II, PhD, Karen Messer, PhD, Laura Z. Rassenti, PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD

Blood (2018) 132 (Supplement 1): 4415.

https://doi.org/10.1182/blood-2018-99-111996

Published: 2018

Journal Articles

ROR1 Expression Is Associated with Oncogenic Dedifferentiation in Chronic Lymphocytic Leukemia

Emanuela M. Ghia, PhD, Michael Y. Choi, MD, George F. Widhopf II, PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD, PhD

Blood (2018) 132 (Supplement 1): 1853.

https://doi.org/10.1182/blood-2018-99-119711

Published: 2018

Journal Articles

Development of Cirmtuzumab Antibody-Drug Conjugates (ADCs) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1)

Yousaf A. Mian, PhD, George F. Widhopf II, PhD, Thanh-Trang Vo, PhD, Katti Jessen, PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD PhD

Blood (2018) 132 (Supplement 1): 1862.

https://doi.org/10.1182/blood-2018-99-119447

Published: 2018

Journal Articles

Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia

Md Kamrul Hasan, Jian Yu, George F. Widhopf, II, Laura Z. Rassenti, Liguang Chen, Zhouxin Shen, Steven P. Briggs, Donna S. Neuberg, Thomas J. Kipps

Blood (2018) 132 (2): 170–178.

https://doi.org/10.1182/blood-2017-12-819383

Published: 2018

Includes: Supplemental data

Journal Articles

Wnt5a Induces ROR1 to Complex with DOCK2 and Promote Proliferation of Chronic Lymphocytic Leukemia Cells

Md Kamrul Hasan, PhD, Jian Yu, PhD, George F. Widhopf II, PhD, Laura Z. Rassenti, PhD, Liguang Chen, PhD, Zhouxin Shen, PhD, Steven P. Briggs, PhD, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 388.

https://doi.org/10.1182/blood.V130.Suppl_1.388.388

Published: 2017

Journal Articles

Durable and Specific Inhibition of ROR1 Signaling Associates with Prolonged Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Treated with Cirmtuzumab

Michael Choi, MD, George F. Widhopf II, PhD, Jian Yu, PhD, Liguang Chen, PhD, Md. Kamrul Hasan, PhD, Laura Z. Rassenti, PhD, Emily Pittman, PhD, Karen Messer, PhD, Charlene Gutierrez, BS, Reilly Lilianna Kidwell, BSc, Charles E. Prussak, PharmD, PhD, Januario E Castro, MD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 829.

https://doi.org/10.1182/blood.V130.Suppl_1.829.829

Published: 2017

Journal Articles

Wnt5a Induces ROR1 to Bind and Activate Cortactin, Which Functions in Planar Cell Polarity and Migration of Chronic Lymphocytic Leukemia Cells

Md Kamrul Hasan, PhD, Jian Yu, PhD, George F. Widhopf II, PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 389.

https://doi.org/10.1182/blood.V130.Suppl_1.389.389

Published: 2017

Journal Articles

Wnt5a Can Induce Activation of Rac1 and Proliferation in Mantle Cell Lymphoma Via a ROR1-Dependent, but BTK-Independent, Signaling Pathway

Jian Yu, PhD, Yun Chen, PhD, Liguang Chen, PhD, Ling Zhang, Laura Z. Rassenti, PhD, George F. Widhopf II, PhD, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 4019.

https://doi.org/10.1182/blood.V130.Suppl_1.4019.4019

Published: 2017

Journal Articles

High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia

Bing Cui, Emanuela M. Ghia, Liguang Chen, Laura Z. Rassenti, Christopher DeBoever, George F. Widhopf, II, Jian Yu, Donna S. Neuberg, William G. Wierda, Kanti R. Rai, Neil E. Kay, Jennifer R. Brown, Jeffrey A. Jones, John G. Gribben, Kelly A. Frazer, Thomas J. Kipps

Blood (2016) 128 (25): 2931–2940.

https://doi.org/10.1182/blood-2016-04-712562

Published: 2016

Includes: Supplemental data

Journal Articles

Wnt5a Induces ROR1 to Complex with HS1, Which Undergoes Tyrosine Phosphorylation and Contributes to Planar-Cell-Polarity Migration in Chronic Lymphocytic Leukemia

Md Kamrul Hasan, PhD, Jian Yu, PhD, Liguang Chen, PhD, Bing Cui, PhD, Zhouxin Shen, PhD, George F. Widhopf, II, PhD, Laura Z. Rassenti, PhD, Steven P. Briggs, PhD, Thomas J. Kipps, MD, PhD

Blood (2016) 128 (22): 301.

https://doi.org/10.1182/blood.V128.22.301.301

Published: 2016

NARROW

Combined Therapy of Zanubrutinib and Zilovertamab in the Inhibition of Invasive Capability of Chronic Lymphocytic Leukemia Cells

Cirmtuzumab (Zilovertamab) Eliminates ROR1 Positive Leukemia Stem Cells By Blocking Niche Dependent ROR1/WNT5a Signaling

Wnt5a Induces ROR1-Dependent NFkB Activation to Upregulate MMP9 and Enhance Invasiveness in Chronic Lymphocytic Leukemia

Wnt5a Induces ROR1 to Interact Grb2 to Enhance Ras Activation in Chronic Lymphocytic Leukemia

Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax

High-Level ROR1 and BCL2, Cancer-Stemness, and BCL2 Mutations Associate with Venetoclax Resistance in Chronic Lymphocytic Leukemia

Wnt5a Induces ROR1-Dependent Upregulation of MMP9 and Enhanced Invasiveness in Chronic Lymphocytic Leukemia

Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia

Cirmtuzumab Inhibits Non-Canonical Wnt Signaling without Enhancing Canonical Wnt/β-Catenin Signaling in Chronic Lymphocytic Leukemia

Wnt5a Induces ROR1 Dependent Tyrosine Phosphorylation of DOCK2, and Enhanced Activation of ERK to Promote Proliferation of CLL Cells

Cirmtuzumab Blocks Production of Proinflammatory Factors By Inhibiting Wnt5a/ROR1 Induced Activation of NF-Kappa B in Chronic Lymphocytic Leukemia

ROR1 Expression Is Associated with Oncogenic Dedifferentiation in Chronic Lymphocytic Leukemia

Development of Cirmtuzumab Antibody-Drug Conjugates (ADCs) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1)

Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia

Wnt5a Induces ROR1 to Complex with DOCK2 and Promote Proliferation of Chronic Lymphocytic Leukemia Cells

Durable and Specific Inhibition of ROR1 Signaling Associates with Prolonged Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Treated with Cirmtuzumab

Wnt5a Induces ROR1 to Bind and Activate Cortactin, Which Functions in Planar Cell Polarity and Migration of Chronic Lymphocytic Leukemia Cells

Wnt5a Can Induce Activation of Rac1 and Proliferation in Mantle Cell Lymphoma Via a ROR1-Dependent, but BTK-Independent, Signaling Pathway

High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia

Wnt5a Induces ROR1 to Complex with HS1, Which Undergoes Tyrosine Phosphorylation and Contributes to Planar-Cell-Polarity Migration in Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only